疗法诱导的衰老有助于阿贝马西克利布在患有脱差性脂类肉瘤的患者中的有效性
Caroline E Gleason1,2, Mark A Dickson3, Mary E Klein Dooley1,2
1Louis V. Gerstner Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.
概括
像abemaciclib这样的CDK4/6抑制剂通过诱导衰老,在非分化脂肪瘤中表现有前途. 然而,这可能会导致耐药性,这表明老化药可能会改善治疗持续时间.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 免疫学 免疫学 免疫学
背景情况:
- 细胞衰老在瘤生长和对治疗的反应中起着复杂的作用.
- CDK4/6抑制剂 (CDK4/6i) 正在成为各种癌症的治疗策略.
- 了解衰老诱导的机制及其对瘤微环境的影响对于优化治疗至关重要.
研究的目的:
- 为了研究衰老在CDK4/6抑制期间瘤生长中的作用.
- 评估abemaciclib在患有渐进性分离性脂肪瘤 (DDLS) 的患者的疗效和安全性.
- 探索热转换的分子调节剂及其对治疗反应和耐药性的影响.
主要方法:
- 在DDLS患者中进行了abemaciclib的II期临床试验.
- 在脂肪肉瘤细胞系中进行了临床前研究,以确定 geroconversion 调节器.
- 分析瘤样本以检测细胞衰老和免疫细胞透 (TILs).
主要成果:
- 阿贝马西克利布在DDLS患者中显示出有前途的无进展生存期 (中位数为33周).
- ANGPTL4被确定为热转换的关键调节者,将衰老与炎症联系起来.
- 衰老诱导与白细胞透的增加相关,但也与以后的治疗抵抗有关.
结论:
- 阿贝马西克利布在DDLS中耐受性良好且活跃,诱导瘤细胞衰老.
- ANGPTL4在日后转换中的作用阐明了CDK4/6i诱导的衰老如何影响瘤免疫微环境.
- 将老化剂与abemaciclib结合使用可能会在一小部分患者中提高反应持续时间.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:15Replicative Cell Senescence
3.7K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.7K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K